Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Race Oncology Ltd has received ethics approval from the Bellberry Human Research Ethics Committee to initiate a Phase 1 clinical trial of RC220 bisantrene, both alone and in combination with doxorubicin, for patients with solid tumors. This approval marks a significant milestone, enabling the company to begin patient enrollment at the Southside Cancer Care Centre in March 2025, with plans to expand to additional sites. The trial’s success could enhance Race Oncology’s position in the industry by advancing their cardioprotective cancer therapies, potentially benefiting stakeholders through improved treatment options.
More about Race Oncology Ltd.
Race Oncology Ltd is a biotechnology company focused on developing novel cancer therapies. The company specializes in creating cardioprotective treatments with anticancer benefits, aiming to improve patient outcomes in the oncology sector.
YTD Price Performance: -25.93%
Average Trading Volume: 80,528
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$183.3M
See more insights into RAC stock on TipRanks’ Stock Analysis page.